Nagai H, Yakuo I, Togawa M, Arimura A, Matsuura N, Koda A, Hamano S, Ujiie A, Nakazawa M
Department of Pharmacology, Gifu Pharmaceutical University, Japan.
Prostaglandins Leukot Med. 1987 Dec;30(2-3):111-21. doi: 10.1016/0262-1746(87)90141-7.
The effect of OKY-046, a newly synthetized thromboxane A2 (TxA2) synthetase inhibitor, on IgE mediated experimental asthma in guinea pigs was investigated. Indomethacin, a cyclooxygenase inhibitor, and tranilast (N-5'), a potent anti-allergic agent, were used as comparative drugs. OKY-046 clearly improved asthmatic respiratory disorders in guinea pigs. Whereas indomethacin had no effect on the changes of asthmatic respiration, tranilast significantly inhibited the changes. OKY-046 inhibited the in vitro antigen-induced contraction of sensitized guinea pig lung parenchyma. This antigen-induced contraction was also inhibited by tranilast, but not by indomethacin. OKY-046 inhibited the contractions of lung parenchyma caused by leukotriene C4, D4 and E4 (LTC4, LTD4 and LTE4), but not by histamine. Indomethacin showed a biphasic action on the contractile responses caused by histamine and LTD4 Consequently, contractions due to either agonist at low concentrations were inhibited by indomethacin, but those at high concentrations were enhanced. Tranilast inhibited the contraction of lung parenchyma induced by a low concentration of LTD4 but not that produced by histamine. Moreover, OKY-046 inhibited an elevation of concentration of thromboxane B2 (TxB2) in guinea pig lung perfusate after infusion of LTC4 but did not affect the elevation of 6-keto-PGF1 alpha. OKY-046 had no effect on the antigen-induced release of histamine but it inhibited the release of the slow reacting substance of anaphylaxis (SRS-A) from sensitized chopped lung tissues. Indomethacin at a high concentration inhibited the release of histamine but did not affect the release of SRS-A. Tranilast clearly inhibited the release of both mediators. These results suggest that OKY-046 inhibits IgE mediated experimental asthma in guinea pigs and that its main mechanism is related to the inhibition of LT induced contraction of airway smooth muscle and the release of SRS-A from lung tissues.
研究了新合成的血栓素A2(TxA2)合成酶抑制剂OKY-046对豚鼠IgE介导的实验性哮喘的作用。将环氧化酶抑制剂吲哚美辛和强效抗过敏药曲尼司特(N-5')用作对照药物。OKY-046明显改善了豚鼠的哮喘性呼吸障碍。而吲哚美辛对哮喘性呼吸变化没有影响,曲尼司特则显著抑制了这些变化。OKY-046抑制了体外抗原诱导的致敏豚鼠肺实质收缩。这种抗原诱导的收缩也受到曲尼司特的抑制,但不受吲哚美辛的抑制。OKY-046抑制了白三烯C4、D4和E4(LTC4、LTD4和LTE4)引起的肺实质收缩,但不受组胺的影响。吲哚美辛对组胺和LTD4引起的收缩反应表现出双相作用。因此,低浓度激动剂引起的收缩受到吲哚美辛的抑制,但高浓度时则增强。曲尼司特抑制低浓度LTD4诱导的肺实质收缩,但不抑制组胺引起的收缩。此外,OKY-046抑制了LTC4注入后豚鼠肺灌流液中血栓素B2(TxB2)浓度的升高,但不影响6-酮-PGF1α的升高。OKY-046对抗原诱导的组胺释放没有影响,但它抑制了致敏切碎肺组织中过敏反应慢反应物质(SRS-A)的释放。高浓度的吲哚美辛抑制组胺的释放,但不影响SRS-A的释放。曲尼司特明显抑制了两种介质的释放。这些结果表明,OKY-046抑制豚鼠IgE介导的实验性哮喘,其主要机制与抑制LT诱导的气道平滑肌收缩和肺组织中SRS-A的释放有关。